Ronac Mamtani, MD, MSCE

Ronac Mamtani, MD, MSCE, is an Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania.

Articles by Ronac Mamtani, MD, MSCE

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

ByRonac Mamtani, MD, MSCE,Ramy Sedhom, MD,Ryan D. Chow, MD

February 5th 2026

Ramy Sedhom, MD, Ryan Chow, MD, and Ronac Mamtani, MD, MSCE, discuss dose reducing enfortumab vedotin to improve tolerability, without in patients with bladder cancer

Ronac Mamtani, MD, MSCE

Articles by Ronac Mamtani, MD, MSCE

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

Latest Updated Articles

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC

On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care

Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD

Enfortumab Vedotin Dose Reductions May Improve Tolerability Without Impeding OS in Advanced Urothelial Carcinoma

Prophylactic Dexamethasone Fails to Reduce Delayed Neurotoxicity Risk After CAR T-Cell Therapy in Myeloma